Back to Search
Start Over
Novartis drug approved by EU
- Source :
- Wall Street Journal. Europe. Sept 3, 2007, A4
- Publication Year :
- 2007
-
Abstract
- Swiss pharmaceutical firm Novartis AG received approval by the European Union to market a generic version of epoetin alfa, an anti-anemia drug, in Europe. The non-generic version, Eprex, is marketed in Europe by Johnson and Johnson.
- Subjects :
- Novartis AG -- Licensing, certification and accreditation
Novartis AG -- Product introduction
Pharmaceutical industry -- Licensing, certification and accreditation
Pharmaceutical industry -- Product introduction
Generic drugs -- Licensing, certification and accreditation
Generic drugs -- Product introduction
Erythropoietin, Recombinant -- Licensing, certification and accreditation
Erythropoietin, Recombinant -- Product introduction
Banking, finance and accounting industries
Business
Business, international
European Union -- Licensing, certification and accreditation
Subjects
Details
- Language :
- English
- ISSN :
- 09219986
- Database :
- Gale General OneFile
- Journal :
- Wall Street Journal. Europe
- Publication Type :
- News
- Accession number :
- edsgcl.168314826